Evolent Health Inc (EVH) Shares Sold by Granahan Investment Management Inc. MA
Granahan Investment Management Inc. MA lowered its holdings in shares of Evolent Health Inc (NYSE:EVH) by 39.2% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 723,867 shares of the technology company’s stock after selling 467,091 shares during the period. Evolent Health accounts for approximately 0.9% of Granahan Investment Management Inc. MA’s holdings, making the stock its 28th largest position. Granahan Investment Management Inc. MA owned about 0.93% of Evolent Health worth $15,237,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of EVH. NumerixS Investment Technologies Inc bought a new position in Evolent Health during the second quarter worth about $105,000. Quantbot Technologies LP grew its holdings in Evolent Health by 111.4% during the first quarter. Quantbot Technologies LP now owns 10,815 shares of the technology company’s stock worth $154,000 after purchasing an additional 5,698 shares during the period. LPL Financial LLC bought a new position in Evolent Health during the first quarter worth about $184,000. Xact Kapitalforvaltning AB bought a new position in Evolent Health during the first quarter worth about $190,000. Finally, Paloma Partners Management Co bought a new position in Evolent Health during the second quarter worth about $209,000.
Shares of NYSE:EVH opened at $27.65 on Friday. Evolent Health Inc has a 12-month low of $10.30 and a 12-month high of $28.20. The company has a market cap of $2.06 billion, a PE ratio of -39.50 and a beta of 1.22. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.59 and a quick ratio of 2.59.
A number of equities analysts recently commented on the company. ValuEngine upgraded Evolent Health from a “hold” rating to a “buy” rating in a report on Thursday, August 9th. TheStreet upgraded Evolent Health from a “d+” rating to a “c-” rating in a report on Monday, June 4th. Zacks Investment Research upgraded Evolent Health from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a report on Tuesday, July 10th. MED boosted their price objective on Evolent Health from $22.00 to $31.00 and gave the stock an “outperform” rating in a report on Monday, June 18th. Finally, KeyCorp boosted their price objective on Evolent Health from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, June 7th. One analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Evolent Health currently has an average rating of “Buy” and a consensus price target of $28.67.
In other news, CEO Frank J. Williams sold 3,878 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $24.00, for a total transaction of $93,072.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Thomas Peterson III sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $21.21, for a total value of $212,100.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 546,315 shares of company stock valued at $12,823,614. Corporate insiders own 4.82% of the company’s stock.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Further Reading: What are the Benefits of Index Funds?
Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health Inc (NYSE:EVH).
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.